Abstract |
In the present study of 12 boys and 19 girls 2-16 years of age (median, 7 years) on oral 6-mercaptopurine (6MP) and methotrexate (MTX) maintenance therapy (MT) for non-B-cell acute lymphoblastic leukemia (ALL), we found that (a) during MT, 6-thioguanine nucleotides (6TGN) (the major cytotoxic metabolite of 6MP) accumulate in the erythrocytes (E-6TGN); (b) for patients receiving an unchanged dose of 6MP, no significant correlation could be demonstrated between the mean E-6TGN (mE-6TGN) and the dose of 6MP (r = -0.11, P = 0.28) (31 patients); (c) among 21 patients receiving 50-75 mg/m2 6MP, a variation of up to 3 orders of magnitude in mE-6TGN could be demonstrated, with the interindividual coefficient of variation (CV) in mE-6TGN for these patients being 0.31; (d) the median intraindividual CV in E-6TGN at an unchanged dose of 6MP was 0.11 (range, 0.04-0.18); and (e) the degree of myelodepression as measured by the mean white cell count was related to mE-6TGN (r = -0.55, P = 0.0006). These results indicate that E-6TGN could be a useful parameter for monitoring 6MP maintenance chemotherapy, although this needs to be explored in prospective studies.
|
Authors | K Schmiegelow, I Bruunshuus |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 26
Issue 4
Pg. 288-92
( 1990)
ISSN: 0344-5704 [Print] Germany |
PMID | 2369793
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Guanine Nucleotides
- Thionucleotides
- 6-thioguanylic acid
- Mercaptopurine
- Methotrexate
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Dose-Response Relationship, Drug
- Erythrocytes
(metabolism)
- Female
- Guanine Nucleotides
(blood)
- Humans
- Leukopenia
(chemically induced, prevention & control)
- Male
- Mercaptopurine
(administration & dosage, adverse effects)
- Methotrexate
(administration & dosage, adverse effects)
- Monitoring, Physiologic
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy, metabolism)
- Thionucleotides
(blood)
|